97315-18-9

Upstream product

• 621-59-0 isovanillin 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 121042-95-3 (Z)-5-(3-tert-butyldimethylsilyloxy-4-methoxystyryl)-1,2,3-trimethoxybenzene 
• 621-59-0 isovanillin 
• 388566-83-4 1-(3-tert-butyldimethylsilyloxy-4-methoxyphenyl)-2,2-dibromoethene 
• 944282-71-7 (1S,3S,5R,6S)-3-[[3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4-methoxyphenyl]hydroxymethyl]-2-oxobicyclo[3.1.0]hexane-6-carboxylic acid ethyl ester 
• 391213-72-2 (R)-N-Boc-m-hydroxy-p-methoxyphenyl-Gly 
• 586413-60-7 diphenylmethylamino-p-methoxy-m-(tert-butyldimethylsilyloxy)phenylacetonitryle 
• 586413-68-5 (8R,11R,14S)-8-Amino-11-(3,5-dichloro-4-methoxy-phenyl)-4-methoxy-13-methyl-9,12-dioxo-2-oxa-10,13-diaza-tricyclo[14.2.2.1^3,7]henicosa-1⁽¹⁹⁾,3⁽²¹⁾,4,6,16⁽²⁰⁾,17-hexaene-14-carboxylic acid methyl ester 
• 586413-52-7 (8R,11R,14S)-8-tert-Butoxycarbonylamino-11-(3,5-dichloro-4-methoxy-phenyl)-4-methoxy-13-methyl-9,12-dioxo-2-oxa-10,13-diaza-tricyclo[14.2.2.1^3,7]henicosa-1⁽¹⁹⁾,3⁽²¹⁾,4,6,16⁽²⁰⁾,17-hexaene-14-carboxylic acid methyl ester 
• 586413-69-6 (8R,11R,14S)-11-(3,5-Dichloro-4-methoxy-phenyl)-4-methoxy-13-methyl-9,12-dioxo-8-(2,2,2-trifluoro-acetylamino)-2-oxa-10,13-diaza-tricyclo[14.2.2.1^3,7]henicosa-1⁽¹⁹⁾,3⁽²¹⁾,4,6,16⁽²⁰⁾,17-hexaene-14-carboxylic acid methyl ester 
• 586413-70-9 (8R,11R,14S)-11-(3,5-Dichloro-4-hydroxy-phenyl)-4-hydroxy-13-methyl-9,12-dioxo-8-(2,2,2-trifluoro-acetylamino)-2-oxa-10,13-diaza-tricyclo[14.2.2.1^3,7]henicosa-1⁽¹⁹⁾,3⁽²¹⁾,4,6,16⁽²⁰⁾,17-hexaene-14-carboxylic acid 
• 586413-51-6 (S)-2-{[(R)-2-[(R)-2-tert-Butoxycarbonylamino-2-(3-hydroxy-4-methoxy-phenyl)-acetylamino]-2-(3,5-dichloro-4-methoxy-phenyl)-acetyl]-methyl-amino}-3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-propionic acid methyl ester 
• 586413-72-1 (R)-{[(8R,11R,14S)-8-Amino-11-(3,5-dichloro-4-hydroxy-phenyl)-4-hydroxy-5-iodo-13-methyl-9,12-dioxo-2-oxa-10,13-diaza-tricyclo[14.2.2.1^3,7]henicosa-1⁽¹⁹⁾,3⁽²¹⁾,4,6,16⁽²⁰⁾,17-hexaene-14-carbonyl]-amino}-(4-hydroxy-phenyl)-acetic acid methyl ester 
• 586413-54-9 C₄₃H₄₅Cl₂F₃N₄O₁₀Si 
• 586413-71-0 C₄₃H₄₄Cl₂F₃IN₄O₁₀Si 

Relevant academic research and scientific papers

NFSI/KF mediated mild and chemoselective interconversion of aryl TBDMS ethers to their benzene sulfonate

A one pot protocol for the transformation of aryl TBDMS ethers to corresponding benzene sulfonate esters using NFSI (N-flurobenzenesulfonimide)/KF is described. In situ generation of benzenesulfonyl fluoride directs chemoselective cleavage of aryl silyl ethers over alkyl silyl ethers. Electron withdrawing substituent's on aryl ring provided better yield than donating groups. Protecting groups and sensitive functionalities are well tolerated in this methodology. Thus, commercially available inexpensive reagents, mild reaction conditions and step economy are the advantages of this method.

Synthesis and Cytotoxicity Studies of Stilbene Long-Chain Fatty Acid Conjugates

A series of 16 conjugates of the tubulin polymerization inhibitor combretastatin A4 (CA-4) and other functionally related stilbene with four 18-carbon fatty acids, namely, stearic, oleic, linoleic, and linolenic acids, have been synthesized in good yields. These new derivatives have been evaluated against the KB-3-1 (human epidermoid carcinoma), NCI-H460 (human lung cancer), HEK293 (human embryonic kidney), and MCF-7 (human breast adenocarcinoma) cell lines for antiproliferative activity, with the exhibited cytotoxic activities comparable with those of CA-4 and colchicine. Compounds 22 and 23, CA-4 conjugates of linoleic and linolenic acids, respectively, were determined to have exhibited the most active in vitro assays, with compound 23 exhibiting very similar activity to the parent compound against the NCI-H460 cell line. Our studies further delineated the structurally required Z-geometry of the stilbene moiety and that conjugation of the less active E-stilbenes with the most active fatty acid had minimal or no improvement in their respective activities.

3-Vinylazetidin-2-Ones: Synthesis, antiproliferative and tubulin destabilizing activity in MCF-7 and MDA-MB-231 Breast Cancer Cells

Microtubule-targeted drugs are essential chemotherapeutic agents for various types of cancer. A series of 3-vinyl-β-lactams (2-azetidinones) were designed, synthesized and evaluated as potential tubulin polymerization inhibitors, and for their antiproliferative effects in breast cancer cells. These compounds showed potent activity in MCF-7 breast cancer cells with an IC50 value of 8 nM for compound 7s 4-[3-Hydroxy-4-methoxyphenyl]-1-(3,4,5-trimethoxyphenyl)-3-vinylazetidin-2-one) which was comparable to the activity of Combretastatin A-4. Compound 7s had minimal cytotoxicity against both non-tumorigenic HEK-293T cells and murine mammary epithelial cells. The compounds inhibited the polymerisation of tubulin in vitro with an 8.7-fold reduction in tubulin polymerization at 10 μM for compound 7s and were shown to interact at the colchicine-binding site on tubulin, resulting in significant G2/M phase cell cycle arrest. Immunofluorescence staining of MCF-7 cells confirmed that β-lactam 7s is targeting tubulin and resulted in mitotic catastrophe. A docking simulation indicated potential binding conformations for the 3-vinyl-β-lactam 7s in the colchicine domain of tubulin. These compounds are promising candidates for development as antiproiferative microtubule-disrupting agents.

Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance

It is well-known that cisplatin exhibited a broad spectrum of anticancer activities against many solid tumors, but its severe toxicity and drug resistance have largely limited wider clinical applications. Various strategies have been tried to discover new Pt (II) drugs with at least equal activity as well as low toxicity compared to cisplatin, but the inherent problem remains unsolved. Here we report that Pt (IV) complexes comprising a CA-4 analogue, as dual-targeting Pt (IV) prodrug, were synthesized and evaluated for anti-proliferative activity using MTT assay. Among them, complex 19 displayed most potent activity against the tested cancer cell lines, and simultaneously exhibited better cell selectivity between cancer cells and normal cells than that of cisplatin. Mechanism studies revealed that complex 19 effectively induced cell cycle arrest at the G2/M phase and dramatically disrupted the microtubule organization. Moreover, complex 19 significantly induced cell apoptosis and decreased MMP. Importantly, complex 19 significantly inhibited tumor growth in SK-OV-3 xenograft model in vivo without apparent toxicity.

Pd-Catalyzed Conjunctive Cross-Coupling between Grignard-Derived Boron “Ate” Complexes and C(sp2) Halides or Triflates: NaOTf as a Grignard Activator and Halide Scavenger

Catalytic enantioselective conjunctive cross-couplings that employ Grignard reagents are shown to furnish an array of nonracemic chiral organoboronic esters in an efficient and highly selective fashion. The utility of sodium triflate in facilitating this reaction is two-fold: it enables “ate” complex formation and overcomes catalytic inhibition by halide ions.

To replace the double-aryl cycloalkyl derivatives and its preparation method and application

The invention provides a substituent bis-aryl methylene naphthenic base derivative with the structure of a general formula I, as well as medical salt or hydrate thereof. The class of compound can be used as micromolecule tubulin inhibitor, has a canalicul

Diaryl-beta-lactam compounds, and preparation method and application thereof in drug preparation

The invention belongs to the field of synthetic pharmaceutical chemistry, and relates to diaryl-beta-lactam compounds having a structure in a general formula below and having remarkable antitumor activity and application thereof in drug preparation. The invention also comprises application of the compounds, pharmaceutical salts thereof and pharmaceutical compositions thereof in preparation of drugs for preventing or treating tumor-related diseases. The compounds or pharmaceutically acceptable salts thereof provided by the invention can effectively inhibit the growth of nude mouse transplanted tumors in vitro and in vivo through an in-vitro regulation and control mechanism capable of inhibiting the growth of tumor cells by inhibiting tubulin aggregation, and can be used in preparation of drugs for preventing or treating the tumor-related diseases, wherein the tumor-related diseases comprise benign and malignant tumors and other diseases caused by the tumors. The general formula is shown in the specification.

Bioreductively activatable prodrug conjugates of phenstatin designed to target tumor hypoxia

A variety of solid tumor cancers contain significant regions of hypoxia, which provide unique challenges for targeting by potent anticancer agents. Bioreductively activatable prodrug conjugates (BAPCs) represent a promising strategy for therapeutic intervention. BAPCs are designed to be biologically inert until they come into contact with low oxygen tension, at which point reductase enzyme mediated cleavage releases the parent anticancer agent in a tumor-specific manner. Phenstatin is a potent inhibitor of tubulin polymerization, mimicking the chemical structure and biological activity of the natural product combretastatin A-4. Synthetic approaches have been established for nitrobenzyl, nitroimidazole, nitrofuranyl, and nitrothienyl prodrugs of phenstatin incorporating nor-methyl, mono-methyl, and gem-dimethyl variants of the attached nitro compounds. A series of BAPCs based on phenstatin have been prepared by chemical synthesis and evaluated against the tubulin-microtubule protein system. In a preliminary study using anaerobic conditions, the gem-dimethyl nitrothiophene and gem-dimethyl nitrofuran analogues were shown to undergo efficient enzymatic cleavage in the presence of NADPH cytochrome P450 oxidoreductase. Each of the eleven BAPCs evaluated in this study demonstrated significantly reduced inhibitory activity against tubulin in comparison to the parent anti-cancer agent phenstatin (IC50?=?1.0?μM). In fact, the majority of the BAPCs (seven of the eleven analogues) were not inhibitors of tubulin polymerization (IC50?>?20?μM), which represents an anticipated (and desirable) attribute for these prodrugs, since they are intended to be biologically inactive prior to enzyme-mediated cleavage to release phenstatin.

4-AZAPODOPHYLOTOXINS COMPOUNDS

The present disclosure relates to 4-azapodophylotoxins compounds, pharmaceutical compositions comprising such compounds, kits, and methods for using such compounds or pharmaceutical compositions.

β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells

Glucuronidation by uridine 5-diphosphoglucuronosyl transferase enzymes (UGTs) is a cause of intrinsic drug resistance in cancer cells. Glucuronidation of combretastatin A-4 (CA-4) was previously identified as a mechanism of resistance in hepatocellular ca